Hallmarks of Protective Immunity in Sequential Rhinovirus Infections in Humans

Inclusion Criteria

• Subject must be 18-40 years of age
• Subject must read and sign a copy of the approved Consent Form
• Subject must have a serum neutralizing antibody titer of ≤1:2 to rhinovirus type 39 and rhinovirus type 16
• Female subjects must be using an effective birth control method.
• Total IgE <150 IU/ml.

Exclusion Criteria

• Any clinically significant abnormalities of the upper respiratory tract
• Any clinically significant acute or chronic respiratory illness
• Any clinically significant bleeding tendency by history
• Hypertension that requires treatment with antihypertensive medications
• History of angina or other clinically significant cardiac disease
• Any upper respiratory infection or allergic rhinitis in the two weeks prior to the start of the study
• Any medical condition that in the opinion of the Investigator is cause for exclusion from the study
• Use of any anti-inflammatory (steroids or NSAIDs) or cough/cold preparation in the 1 month prior to the study
• Regular use of tobacco in the last 6 months (ie. more than 2 days out of 7) or inability to refrain from smoking during the study
• Inability to refrain from the use of common cold therapies in the 5 days after each rhinovirus challenge.
• Participation in any other clinical drug trial in the month prior to the study
• Female subjects with a positive urine pregnancy screen.